The Partnership’s initiative on cancer drug sustainability has been developed in close collaboration with the Canadian Association of Provincial Cancer Agencies (CAPCA). CPAC’s work comprises three elements:
- An economic Analysis aimed at developing an understanding of the factors driving drug spending and the levers available to influence sustainability
- Developing and applying real-world evidence of approved cancer drugs in decision-making
- Development and dissemination of a pan-Canadian framework of public values and priorities to inform decision-making
The Partnership has completed the first part of its cancer drugs and sustainability initiative by commissioning an evidence synthesis of recent Public Health Agency of Canada (PHAC) and Canadian Institutes of Health Information (CIHI) reports to understand costs drivers from a cancer control perspective. Some drugs and treatments can be healthcare intensive, including those involved in the treatment of cancer patients. Cancer services are subject to distinct funding arrangements, which are the general focus of the present project.
Risks Sciences International (RSI) was the selected vendor who submitted two (2) reports on the Economic Analysis for cancer drug sustainability.
- Evidence Synthesis on Post-Approval Surveillance of Approved Novel Cancer Drugs: RSI conducted an evidence synthesis to identify such post-approval surveillance systems and describe their origins, goals, structures and characteristics. Peer-reviewed articles were identified using structured searches in three databases and the gray literature was evaluated with a Google search. An environmental scan, by interview of selected provincial experts, was also conducted following approval by the University of Ottawa Research Ethics Board.
- Analysis of Factors Driving Cancer Drug Spending and Levers Available to Influence Sustainability: This report focuses on available data from Canada and abroad, specifically, on public and private sector spending on prescribed drugs for treatment of cancer in comparison to the costs of drugs used to treat other, non-cancer diseases.